| 交易日期 | 证券調称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 类出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 1586.97 | 33 | 空部落ち發展貫音 | | M | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 961.8 | 20 | 品 - 品品是有限公司 | 有限公司 1999 | ਨੂੰ | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 673.26 | 14 | 公司 2019 11:30 | | 물 | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 673.26 | 14 | 菜就是这些品番 | | KA | | 2025-09-30 | 康辰药业 | 603590 | 48.09 | 302.97 | 6.3 | 华泰国有限公司限 | 有限公司北 | 질 | | 2 ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Company Summary - KC1036 is a class 1 innovative chemical drug independently developed by the company, with global intellectual property rights [1] - The drug exerts anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting of VEGFR to suppress tumor cell growth [1] - By inhibiting AXL, KC1036 can enhance the host's anti-tumor immune response, thereby preventing immune evasion by tumors [1] - Currently, KC1036 is undergoing clinical research for multiple indications, including gastrointestinal tumors, thymic tumors, and pediatric Ewing sarcoma, with over 300 subjects enrolled in the clinical studies to date [1] - Preliminary clinical results indicate significant anti-tumor activity, along with good safety and tolerability [1]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed Class 1 innovative chemical drug with global intellectual property rights held by the company [1] - The drug exerts anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting of VEGFR and inhibiting tumor cell growth [1] - Inhibiting AXL can enhance the host's anti-tumor immune response, thereby preventing immune evasion by tumors [1] Group 2: Clinical Research - KC1036 is currently undergoing clinical research for multiple indications, including gastrointestinal tumors, thymic tumors, and pediatric rhabdomyosarcoma [1] - Over 300 subjects have been enrolled in the clinical studies for KC1036 to date, with existing results showing outstanding anti-tumor activity, as well as good safety and tolerability [1]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative chemical drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed innovative chemical drug with global intellectual property rights held by the company [1] - The drug exhibits anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting and tumor cell growth suppression [1] - Clinical studies for KC1036 are ongoing for various indications, including gastrointestinal tumors, thymic tumors, and pediatric Ewing sarcoma, with over 300 subjects enrolled to date [1] Group 2: Clinical Trial Results - Preliminary clinical research results indicate significant anti-tumor activity, along with good safety and tolerability profiles for KC1036 [1]

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-054 北京康辰药业股份有限公司 关于 KC1036 联合 PD-1 抗体和含铂化疗一线治疗晚期复发或 转移性食管鳞癌获得临床试验通知书的公告 二、KC1036 研发进展 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京康辰药业股份有限公司（以下简称"公司"）收到国家药品监督管 理局核准签发的化学 1 类创新药 KC1036 片关于"KC1036 联合 PD-1 抗体和含铂 化疗一线治疗晚期复发或转移性食管鳞癌"的临床试验通知书，并将于近期开展临 床试验。现将主要相关情况公告如下： 一、本次批准的基本情况 药品名称：KC1036 片 规格：20 mg、30 mg 受理号：CXHL2500740、CXHL2500741 拟开展适应症：KC1036 联合 PD-1 抗体和含铂化疗一线治疗晚期复发或转移 性食管鳞癌 KC1036 是公司自主研发的化学药品 1 类创新药，公司拥有该产品的全球知识 产权。KC1036 通过抑制 VEGFR2、AXL 等多靶点实 ...

Core Viewpoint - Kangchen Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its innovative chemical drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed innovative chemical drug classified as a Class 1 new drug [1] - The drug targets multiple pathways by inhibiting VEGFR2 and AXL to achieve anti-tumor activity [1] - KC1036 exhibits strong vascular targeting of VEGFR, inhibiting tumor cell growth, and improving host anti-tumor immune response by suppressing AXL, thus preventing immune evasion by tumors [1] Group 2: Clinical Research - Clinical trials for KC1036 are set to commence shortly, with over 300 subjects already enrolled in ongoing clinical studies for multiple indications [1]

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

Group 1 - The stock prices of Mengke Pharmaceutical dropped over 10% [1] - Borui Pharmaceutical and Baicheng Pharmaceutical experienced declines of over 7% [1] - Other companies such as Yuekang Pharmaceutical, Kangchen Pharmaceutical, Yuandong Biological, and Fuxiang Pharmaceutical also saw significant drops in their stock prices [1]

Group 1 - The core point of the news is that Kangchen Pharmaceutical experienced a 5.01% drop in stock price, closing at 52.15 yuan per share, with a trading volume of 137 million yuan and a turnover rate of 1.61%, resulting in a total market capitalization of 8.31 billion yuan [1] - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, focuses on innovative drug research and development, with its main business revenue composition being 70.77% from Suling, 29.15% from Salmon Calcitonin (Mikazis), and 0.09% from other sources [1] Group 2 - According to data, one fund under Xinda Aoya holds a significant position in Kangchen Pharmaceutical, with the Xinao Health China Mixed A Fund (003291) holding 730,600 shares, accounting for 3.38% of the fund's net value, ranking as the tenth largest holding [2] - The Xinao Health China Mixed A Fund has a current scale of 534 million yuan, with a year-to-date return of 34.35%, ranking 2667 out of 8173 in its category, and a one-year return of 43.89%, ranking 3547 out of 8003 [2] Group 3 - The fund managers of Xinao Health China Mixed A Fund are Li Junzhou and Yang Ke, with Li having a tenure of 112 days and a total fund size of 680 million yuan, achieving a best return of 20.57% and a worst return of 20.3% during his tenure [3] - Yang Ke has a tenure of 5 years and 137 days, managing a total fund size of 1.445 billion yuan, with a best return of 55.92% and a worst return of -13.42% during his tenure [3]